{"entity":{"id":"nct06051409","kind":"trial","name":"A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)","aka":["POLARIS-1"],"tldr":"A phase 3 trial of Olverembatinib run by Ascentage Pharma Group Inc., now recruiting.","summary":"A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1) is a phase 3 interventional study registered as NCT06051409 by Ascentage Pharma Group Inc., with 350 participants planned, started 2023-08-31. Conditions listed: Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06051409","url":"https://clinicaltrials.gov/study/NCT06051409"}],"tags":["ctgov-ingest"],"related":[],"cancers":["all-leukemia"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["olverembatinib"],"companies":["ascentage-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06051409","phase":"3","setting":"A Pivotal Registrational Phase 3 Study of Olverembatinib Combined With Chemotherapy Versus Investigator's Choice of TKI Combined With Chemotherapy in Patients With Newly Diagnosed Ph+ ALL","sponsor":"Ascentage Pharma Group Inc.","started":"2023-08-31","startedType":"actual","enrolled":350,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06051409/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"olverembatinib","kind":"drug","name":"Olverembatinib","route":"/drugs/olverembatinib/"}],"company":[{"id":"ascentage-pharma","kind":"company","name":"Ascentage Pharma","route":"/companies/ascentage-pharma/"}]}}